admin
This morning’s Israel Update, dated December 1, 2025, highlighted a major scientific victory that ought to make every free nation sit up and take notice: researchers at Tel Aviv University report a breakthrough RNA-based approach that appears to halt and even reverse nerve damage in laboratory models of ALS. This kind of translational science — moving bench discoveries toward real-world treatments — is exactly the kind of practical innovation that conservative Americans have long championed when markets and minds are allowed to work.
The researchers identified a deficiency of microRNA-126 at the neuromuscular junction that allows toxic TDP-43 protein to accumulate, and restoring that RNA in cell and animal studies reduced the damage and promoted nerve regeneration — a clear, targeted mechanism that gives real hope where there was only despair. These are early-stage results done in mice and cell cultures, but the science is specific, reproducible, and aimed at solving the root cause rather than slapping on symptomatic band-aids.
Let’s be blunt: this is the kind of medical progress America should be racing to support, not hamstrung by endless regulatory theater or funding priorities that favor politics over patients. Conservative leaders should push for public-private partnerships with Israeli labs and fast-track collaborative clinical trials so American patients get access sooner. If our policymakers prefer virtue signaling to vibrant scientific cooperation, then families with ALS victims will continue to suffer while breakthroughs gather dust.
Israel’s medical ecosystem has been producing promising ALS work for years — from Hadassah’s encouraging clinical trials to private biotech advances and university spin-offs — showing that a nation committed to science and enterprise can punch well above its weight. Those efforts, including cell therapies and other novel approaches, reinforce that this new RNA finding is not an isolated flash but part of a broader Israeli commitment to curing neurodegeneration. The evidence of multiple parallel efforts should compel Washington to act, not applaud from the sidelines.
On a lighter but no-less-inspiring note, Israel Correspondent Jodie Cohen spoke with Walter Bingham, who Guinness certified as the world’s oldest working journalist back in 2021 and who has refused to let age or trendiness define his craft. Bingham’s life and continued work are a rebuke to an age that too often dismisses experience and hard-won wisdom; his example reminds conservatives that longevity of service and a commitment to truth still matter.
Bingham’s interview is the kind of human story the mainstream media no longer values — yet it’s precisely the sort of thing that conservatism celebrates: grit, duty, and a refusal to be silenced by fashionable narratives. He represents a bridge from the classical virtues of journalism to today’s chaotic information age, proving that older Americans still contribute muscle and muscle-memory to national life. If the press corps won’t honor that, the conservative movement must.
If you care about curing disease, protecting innovation, and celebrating the sort of individual resilience that built the West, then December 1, 2025 should be a call to action. Demand bipartisan support for clinical partnerships with Israeli scientists, insist regulators prioritize life-saving trials, and vote for leaders who recognize that free markets and strong alliances deliver far more than empty rhetoric. The patients waiting for an ALS breakthrough don’t have time for bureaucracy — and neither do the families who love them.
